Patient-Reported Outcomes Instruments Need Validation Before Pivotal Trials
Executive Summary
Patient-reported outcomes instruments should be validated prior to use in a pivotal clinical trial, FDA Antimicrobial Drug Development & Resistance Initiatives Lead Medical Officer John Powers told a Drug Information Association webinar on FDA's PRO draft guidance April 5
You may also be interested in...
Patient-Reported Outcomes Guidance Needs Flexibility, Industry Tells FDA
FDA's draft guidance on patient-reported outcomes (PROs) should offer both greater flexibility and detail, industry commenters told the agency
Patient-Reported Outcomes Guidance Needs Flexibility, Industry Tells FDA
FDA's draft guidance on patient-reported outcomes (PROs) should offer both greater flexibility and detail, industry commenters told the agency
Patient-Reported Outcome Claims In Labeling Should Be Specific To Evidence
Patient-reported outcome instruments that measure simple concepts are not adequate to support complex claims in labeling, FDA said